The recent pandemic inspired Bayer to a proof-of-concept (POC) study that identified a viable solution for replacing in-person site selection visits. The big pharma company hoped that in doing so, their CRAs could remotely complete monitoring activities related to selection, initiation, monitoring, and closeout.
Bayer chose to try Signant Health’s Virtual Monitoring solution to:
- Find a safe alternative to on-site visits
- Assess if the tool streamlined site assessments
- Determine if virtual SSVS could be performed without compromising the visit quality
Read the case study to learn the encountered challenges and final results.